Monday, 4 March, 2024
HomeQuick diagnosesAdvaxis orphan drug

Advaxis orphan drug

Advaxis, a leader in developing cancer immunotherapies has announced it has been granted [b]Orphan Drug Designation[/b] from the [b]US Food and Drug Administration Office of Orphan Products Development[/b] for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer. The Orphan Drug Designation is granted to drug therapies intended to treat diseases or conditions that affect fewer than 200,000 people in the US.

[link url=]Full News-Medical report[/link]

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.